TargImmune Therapeutics AG logo

TargImmune Therapeutics AG

TargImmune Therapeutics AG is a private Swiss-based biotechnology firm focused on drug development using novel targeted immunotherapies.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.targimmune.com
Founded2016
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Elisabethenstrasse 43, 4051
Basel
Switzerland
Email
Contact Number
+41 61 225 1926

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://in.linkedin.com/company/targimmune-therapeutics-ag” connections=”true” suffix=””]

The TargImmune technology platform known as CTPIC (ÇCancer Targeted delivery of pIC), was in-licensed from the Hebrew University of Jerusalem, encompasses a proprietary non-viral vector to target receptors that are overexpressed on cancer cells. Once at the target cell, the vector delivers an immune-modulating agent (poly-IC or pIC) into the cell, which then triggers apoptosis (programmed cell death) and an immune response against the cancer.

In July 2017, Race Oncology Limited (ASX: RAC) and TargImmune Therapeutics forms a new joint venture company called Race Immunotherapeutics, to focus on developing new and improved cancer therapies based on combining Bisantrene (Races cancer chemotherapy drug) with TargImmunes targeted cancer therapy technology. The new company is equally owned by both companies with core development work to be conducted by TargImmune scientists in Basel.